Matt Larew
Stock Analyst at William Blair
(0.34)
# 4,390
Out of 5,242 analysts
16
Total ratings
27.27%
Success rate
-22.77%
Average return
Main Sectors:
Stocks Rated by Matt Larew
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Upgrades: Outperform | n/a | $23.98 | - | 1 | Mar 31, 2026 | |
| WAT Waters | Initiates: Outperform | n/a | $341.32 | - | 1 | Jan 5, 2026 | |
| CRL Charles River Laboratories International | Upgrades: Outperform | n/a | $156.03 | - | 1 | Oct 6, 2025 | |
| TMO Thermo Fisher Scientific | Initiates: Outperform | n/a | $451.79 | - | 1 | Aug 19, 2025 | |
| MXCT MaxCyte | Downgrades: Market Perform | n/a | $1.07 | - | 2 | Aug 7, 2025 | |
| MRVI Maravai LifeSciences Holdings | Downgrades: Market Perform | n/a | $4.43 | - | 1 | Nov 8, 2024 | |
| DNA Ginkgo Bioworks Holdings | Downgrades: Underperform | n/a | $7.72 | - | 3 | May 10, 2024 | |
| ATR AptarGroup | Upgrades: Outperform | n/a | $115.26 | - | 1 | Apr 29, 2024 | |
| TECH Bio-Techne | Initiates: Outperform | n/a | $46.70 | - | 1 | Aug 28, 2023 | |
| AVTR Avantor | Downgrades: Market Perform | n/a | $7.88 | - | 1 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $7.51 | - | 2 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $53.66 | - | 1 | Jun 29, 2021 |
10x Genomics
Mar 31, 2026
Upgrades: Outperform
Price Target: n/a
Current: $23.98
Upside: -
Waters
Jan 5, 2026
Initiates: Outperform
Price Target: n/a
Current: $341.32
Upside: -
Charles River Laboratories International
Oct 6, 2025
Upgrades: Outperform
Price Target: n/a
Current: $156.03
Upside: -
Thermo Fisher Scientific
Aug 19, 2025
Initiates: Outperform
Price Target: n/a
Current: $451.79
Upside: -
MaxCyte
Aug 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.07
Upside: -
Maravai LifeSciences Holdings
Nov 8, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $4.43
Upside: -
Ginkgo Bioworks Holdings
May 10, 2024
Downgrades: Underperform
Price Target: n/a
Current: $7.72
Upside: -
AptarGroup
Apr 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $115.26
Upside: -
Bio-Techne
Aug 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $46.70
Upside: -
Avantor
Jul 31, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $7.88
Upside: -
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $7.51
Upside: -
Jun 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $53.66
Upside: -